Skip to main content

Table 1 Clinicohistopathologic features of the studied population

From: Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers

Tumor urine samples
  Mean ± SD (range)
 Age (yr) 67.5 ± 7.9 (45–85)
 Gland weight (g)a 48.21 ± 22.88 (16–180)
 Serum PSA (ng/ml)b 13.76 ± 36.1 (0.94–365)
  Levels N patients (%)
 PSA (ng/ml)b 0–4 6 (4)
4–10 96 (65)
> 10 46 (31)
 Gleason scorec < 7 69 (46)
≥ 7 81 (54)
 Staged T1 30 (27)
T2 74 (65)
T3 8 (7)
T4 1 (1)
 Treatment RP 69 (46)
RT 29 (19)
CRT 23 (15)
AS 23 (15)
HT 7 (5)
Control urine samples
  Mean ± SD (range)
 Age (yr) 67.2 ± 12 (21–97)
 Serum PSA (ng/ml)e 1.8 ± 1.06 (0.25–3.95)
  N controls (%)
 BPH/Prostatitis 35 (48)
 LUTS 18 (25)
 Lithiasis 5 (7)
 Urethral stenosis 4 (5)
 Others 11 (15)
  1. Abbreviations: SD Standard Deviation, RP Radical prostatectomy, RT Radiotherapy, CRT Cryotherapy, AS Active surveillance, HT Hormonal therapy, BPH Benign Prostate Hyperplasia, LUTS Low Urinary Tract Symptom
  2. aData available for 98 PCa patients; bData available for 148 PCa patients; cData available for 150 PCa patients; dData available for 113 PCa patients. Stage T1, only for those patients with no pathological stage available (Eg. RT, CRT, AS and HT); eData available for 65 controls